Investing.com -- The U.S. Centers for Medicare & Medicaid Services (CMS) on Tuesday announced a new list of branded medications for the third round of the Medicare Drug Price Negotiation Program. The ...

Eli Lilly is the leader in GLP-1 weight loss drugs today, but that advantage won't last forever.

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

The S&P 500 rose as traders braced for a big week, with key earnings reports and a U.S. monetary policy meeting.

In the latest trading session, Eli Lilly (LLY) closed at $1,064.29, marking a -2.12% move from the previous day. This change lagged the S&P 500's 0.03% gain on the day. Elsewhere, the Dow saw a ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Alumis, Aktis Oncology, and W.R. Berkley saw significant insider buying last week. There were a handful of other notable ...

Parnassus Core Select ETF (PRCS) targets 25 high-quality large-cap stocks for long-term growth. Read the full analysis for ...

Although the stock is trading at a premium valuation, the company’s outstanding operational performance, strong financial ...

Major stock indexes finished mostly lower Wednesday, with the Dow Jones Industrial Average and S&P 500 reversing course after setting fresh all-time highs.

Eli Lilly leads in the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has ...